RIOMET Drug Patent Profile

Which patents cover Riomet, and what generic alternatives are available?

Riomet is a drug marketed by Ranbaxy and Sun Pharm and is included in two NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in RIOMET is metformin hydrochloride. There are forty-nine drug master file entries for this compound. Eighty-one suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Riomet

A generic version of RIOMET was approved as metformin hydrochloride by CHARTWELL on January 24^th, 2002.

Summary for RIOMET

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	41
Patent Applications:	38
Drug Prices:	Drug price information for RIOMET
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RIOMET
What excipients (inactive ingredients) are in RIOMET?	RIOMET excipients list
DailyMed Link:	RIOMET at DailyMed

See drug prices for RIOMET

See drug sales revenues for RIOMET

Recent Clinical Trials for RIOMET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Early Phase 1
Washington State University	Early Phase 1
National Institutes of Health (NIH)	Early Phase 1

See all RIOMET clinical trials

Pharmacology for RIOMET

Drug Class

Biguanide

Paragraph IV (Patent) Challenges for RIOMET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RIOMET	Oral Solution	metformin hydrochloride	500 mg/5 mL	021591	1	2018-02-02

US Patents and Regulatory Information for RIOMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ranbaxy	RIOMET	metformin hydrochloride	SOLUTION;ORAL	021591-001	Sep 11, 2003		DISCN	Yes	No
Sun Pharm	RIOMET ER	metformin hydrochloride	FOR SUSPENSION, EXTENDED RELEASE;ORAL	212595-001	Aug 29, 2019		DISCN	Yes	No	9,962,336		Y

Expired US Patents for RIOMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ranbaxy	RIOMET	metformin hydrochloride	SOLUTION;ORAL	021591-001	Sep 11, 2003	6,890,957

International Patents for RIOMET

See the table below for patents covering RIOMET around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	7659801
Brazil	0113102
Canada	2416767

Supplementary Protection Certificates for RIOMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0861666	07C0006	France		PRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
1412357	CA 2008 00035	Denmark		PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID
1412357	PA2008013	Lithuania		PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716

Last updated: June 8, 2026

RIOMET (metformin hydrochloride oral solution): Market dynamics and financial trajectory

RIOMET is a metformin hydrochloride oral solution positioned in type 2 diabetes treatment where generic metformin oral liquids dominate and pricing pressure is structurally high. Financial trajectory is driven by (1) competition from authorized and uncertified generic metformin liquids, (2) payer formularies that often prefer lower-cost generics, and (3) product-level substitution dynamics versus metformin tablets and extended-release (ER) tablets. Across the U.S., RIOMET’s lifecycle sits in a mature, generics-heavy segment with limited scope for sustained premium pricing.

What is RIOMET and how does it compete in the metformin diabetes drug market?

RIOMET is an oral liquid formulation of metformin hydrochloride for the treatment of type 2 diabetes mellitus. Metformin remains the backbone of first-line therapy in many guidelines and payer protocols, but the addressable market is fragmented across:

• Immediate-release metformin tablets
• Extended-release (ER) metformin tablets
• Generic oral solutions and suspensions
• Delivery-convenience segments (e.g., patients who need liquids)

Core market dynamic: The metformin molecule is no longer differentiated by brand-level patent exclusivity in most geographies, shifting competition to price, access, and patient-specific formulation needs (liquid vs solid). RIOMET’s commercial durability depends on maintaining coverage where oral solution is medically necessary or preferred.

How does RIOMET’s positioning differ from metformin tablets and metformin ER?

• Oral solution advantage: dosing flexibility for patients unable to swallow tablets and in pediatric contexts where liquid formulations can simplify titration.
• Oral solid economics: tablets and ER formulations usually benefit from lower unit costs and broad payer preferences.
• Net effect: RIOMET competes on niche “liquid requirement” rather than broad formulary preference when formularies treat metformin products as interchangeable.

What payer and channel forces shape RIOMET’s sales trajectory?

• Formulary substitution: many formularies prefer the lowest net cost generic metformin IR/ER products; oral solution can still win if a plan covers it without a high-tier restriction.
• PBM contracting: PBMs can steer volume to preferred generics via rebates and formulary placement.
• Switching behavior: clinicians may switch patients between metformin IR, ER, and liquids based on tolerability, dosing convenience, and cost.

What market dynamics drive metformin oral solution pricing and volume?

Metformin oral solution pricing is constrained by two structural forces:

1. Ubiquity of generic alternatives: multiple suppliers offer metformin solution, typically compressing net pricing to near-generic parity.
2. Interchangeability at the molecule level: payers evaluate access using ingredient equivalence and relative cost rather than brand differentiation.

How does competition from generic metformin oral solutions affect RIOMET revenues?

• Downward price pressure: increased generic competition generally reduces branded net price and increases promotional reliance.
• Volume volatility: even small changes in formulary tiering or rebate programs can shift demand toward preferred generics.
• Channel impact: wholesaler ordering patterns often track contract and PBM preference more than clinical nuance for liquid formulations.

What role do tablets and ER products play in RIOMET cannibalization risk?

• Switching from liquid to tablet: some patients and prescribers prefer solids when tolerability and swallowing issues improve.
• Switching from IR liquid to ER tablets: ER’s dosing convenience can attract steady-state maintenance patients, reducing oral solution growth potential.

How has RIOMET’s financial trajectory likely evolved through the generics era?

In mature metformin categories, branded product financial trajectories typically follow a playbook:

• Peak or early growth post-launch,
• Then sustained erosion as generics gain coverage and volume share,
• Followed by stabilization at lower, niche-driven volumes.

For RIOMET, the financial trajectory is expected to have been dominated by:

• Loss of brand pricing leverage after generic entry and increased PBM contracting pressure
• Limited reinvigoration absent a meaningful differentiation driver (device, biologic-like complexity, or exclusive formulation patent moat that supports premium access)
• Persistent but narrower demand base among patients who need oral liquid dosing

What KPIs best explain RIOMET sales movement in practice?

• Net sales trend by quarter
• Prescription counts and TRx growth or decline
• Average net price (ANP) and rebate intensity
• Share of prescriptions within “metformin solution” vs broader metformin category
• Formulary placement changes by top PBMs and major plans

What does a competitive landscape for metformin oral solutions imply for RIOMET market share?

The metformin category has many suppliers, but the key question for RIOMET is whether it can hold share in the subset of “solution-appropriate” patients.

Where RIOMET can hold share

• Patients with swallowing limitations
• Situations requiring fine titration with liquid dosing
• Pediatric or specific caregiver administration workflows
• Patients stabilized on RIOMET who face fewer barriers to continuation than switching to another solution

Where RIOMET loses share

• Plans where preferred alternatives are tablet/ER products with stronger formulary incentives
• Oralsolution contracting that shifts volume to a low-cost preferred generic supplier
• Step-therapy policies or clinical pathways that push conversion to lower-cost metformin products

What is RIOMET’s revenue exposure and upside/downside risk profile?

Downside risk: high. Revenue depends on ongoing coverage and net pricing in a category with frequent generic substitution. If preferred supplier arrangements change, RIOMET volume can drop quickly.

Upside risk: limited. Upside requires a coverage moat that can persist, such as:

• Stable formulary positioning as a preferred solution,
• Contracting that sustains net price,
• Or clinical practice patterns favoring solution retention.

In a commodity molecule market, upside is usually capped unless RIOMET’s solution differentiates on access or is the last remaining covered option in a narrow segment.

What regulatory and reimbursement factors influence RIOMET adoption and continuity?

RIOMET’s adoption is largely reimbursement-driven:

• Medicaid and commercial formularies
• Medicare Part D plan formularies
• PBM preferred drug lists
• Prior authorization or quantity limits where liquid formulations are treated differently than solids

Even when clinicians consider liquid formulations medically appropriate, payer policy often determines whether RIOMET or another solution supplier captures the dispensed volume.

How does RIOMET compare commercially with other metformin formulations?

Commercial comparables:

• Generic metformin IR tablets (lowest-cost default in many plans)
• Generic metformin ER tablets (higher convenience, sometimes better formulary position)
• Generic metformin oral solutions (often the most direct direct-competition substitute for RIOMET)

Relative commercial dynamics

• Tablets (IR/ER): broad access, strongest formulary inclusion, typically lower unit economics
• Oral solutions: narrower access but can win on medical necessity and dosing convenience
• Net effect: RIOMET tends to track solution-share dynamics rather than overall metformin category expansion.

What is the likely sales and profitability trajectory for RIOMET in the U.S. market?

Profitability in mature generic-substitutable markets is driven by net price after rebates and wholesaler/discount structures. For RIOMET, the trajectory typically follows:

• Net sales erosion from generic pressure
• Margin compression from contracting and rebate intensity
• Continued reliance on stable niche volume to support distribution

This produces a financial profile characterized by:

• Stable-to-declining prescription base over time if coverage weakens
• Low revenue growth unless PBM or payer preferences shift back in favor of RIOMET as a covered solution

Key Takeaways

• RIOMET is exposed to structurally high generic substitution risk because it is metformin in a mature diabetes category.
• Market dynamics favor the lowest net cost metformin products on formularies, typically tablets or preferred generics, limiting RIOMET’s growth runway.
• RIOMET financial trajectory is likely dominated by niche liquid-appropriate demand and by PBM formulary and contracting outcomes that determine solution-specific share.
• Upside is constrained unless RIOMET retains preferred solution status and sustains net pricing; downside is amplified by rapid switching to preferred generic suppliers.

FAQs

1. How do PBM formulary tiers typically impact RIOMET net sales versus generic metformin solutions?
2. What substitution patterns are most common for patients moving between metformin oral solution and metformin ER tablets?
3. How does Medicare Part D coverage affect access and continuity for RIOMET compared with metformin tablets?
4. What pricing and rebate dynamics usually determine branded metformin oral solution profitability in the U.S.?
5. How does seasonal variability in diabetes diagnosis and prescription behavior affect metformin oral solution demand?

References

1. APA (general formatting).